SEC Form 3 · accession 0001209191-18-052298
Urovant Sciences Ltd. · UROV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nori Ebersole
Officer — SVP&CHRO-Urovant Sciences,Inc.
Period of report
Sep 26, 2018
Accepted (ET)
Sep 26, 2018 · 4:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001740547
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | holding | — | — | — | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.64 | holding | — | — | — | — | Jan 21, 2028 | Common Shares | 100,125 | — | D |
Explanation of responses
- F125% of the total shares underlying the option shall vest and become exercisable on December 18, 2018; the remaining shares vest in 36 equal monthly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date.
Remarks
Exhibit List - Exhibit 24.1 - Power of Attorney